RAPID INITIAL DECLINE IN BCR-ABL LEVELS IS ASSOCIATED WITH SUPERIOR RESPONSES IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB

被引：0
|
作者：
Stein, A. [1 ]
Shou, Y. [1 ]
Bottino, D. [2 ]
Chia, Y. L. [1 ]
Woodman, R. [2 ]
Martinelli, G. [3 ]
Hughes, T. [4 ]
Mueller, M. [5 ]
Beppu, L. [6 ]
Gottardi, E. [7 ]
Branford, S. [8 ]
Soverini, S. [3 ]
Goh, H. [9 ]
Hochhaus, A. [10 ]
Kim, D. [9 ]
Saglio, G. [7 ]
Radich, J. [6 ]
机构：
[1] Novartis Inst BioMed Res, Cambridge, MA USA
[2] Nova Pharmaceut Corp, E Hanover, NJ USA
[3] Univ Bologna, Bologna, Italy
[4] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
[5] Heidelberg Univ, Med Fak Mannheim, D-6800 Mannheim, Germany
[6] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[7] Univ Turin, Orbassano, Italy
[8] SA Pathol, Adelaide, SA, Australia
[9] Catholic Univ Korea, Seoul, South Korea
[10] Univ Klinikum Jena, Jena, Germany
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0139
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [1] BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
    Kim, D.
    Saglio, G.
    Martinelli, G.
    Shou, Y.
    Stein, A. M.
    Woodman, R. C.
    Kantarjian, H.
    Hughes, T. P.
    Radich, J. P.
    Hochhaus, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] RESPONSE TO NILOTINIB IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DIFFERENT BCR-ABL TRANSCRIPT TYPES
    Saglio, S.
    Hughes, T.
    Kim, D. W.
    Hanfstein, B.
    Gottardi, E.
    Branford, S.
    Goh, H.
    Beppu, L.
    Soverini, S.
    Shou, Y.
    Stein, A.
    Woodman, R.
    Kantarjian, H.
    Radich, J.
    Hochhaus, A.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 342 - 343
  • [3] Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Hochhaus, Andreas
    Kim, Dong-Wook
    Martinelli, Giovanni
    Hughes, Timothy P.
    Soverini, Simona
    Branford, Susan
    Muller, Martin C.
    Erben, Philipp
    Haque, Ariful
    Shou, Yaping
    Saglio, Giuseppe
    Radich, Jerald P.
    BLOOD, 2008, 112 (11) : 1103 - 1104
  • [4] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G. J.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Castagnetti, F.
    le Coutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.
    Radich, Jerald P.
    Martinelli, Giovanni
    Hochhaus, Andreas
    Gottardi, Enrico
    Soverini, Simona
    Branford, Susan
    Mueller, Martin C.
    Beppu, Lan
    Shou, Yaping
    Haque, Ariful
    Woodman, Richard C.
    Kantarjian, Hagop M.
    Hughes, Timothy P.
    Kim, Dong-Wook
    Saglio, Giuseppe
    BLOOD, 2009, 114 (22) : 464 - 465
  • [6] Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
    Hochhaus, A.
    Saglio, A.
    Kantarjian, H.
    Haque, A.
    Shou, Y.
    Woodman, R. C.
    Hughes, T. P.
    Radich, J. P.
    Martinelli, G.
    Kim, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukaemia in chronic phase (CML-CP): updated phase 2 results
    Clark, R.
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    le Coutre, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 57 - 58
  • [8] ANALYSIS OF BCR-ABL MUTATIONS IN MEXICAN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT PHILADELPHIA-CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH plus CML) TREATED WITH NILOTINIB
    Ayala, J. L.
    Hurtado, R.
    Delgado, N.
    Vargas, P.
    Meillon, L.
    Tapia, N.
    Alvarado, M.
    De Diego, J.
    Azaola, P.
    Gonzalez, M.
    Lugo, Y.
    Hernandez, R.
    Kassack, J. J.
    Cleto, S.
    Nambo, M.
    Reyes, G.
    Cantu, O.
    Aguayo, A.
    Mucius, I.
    Herrera, A.
    Nacho, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 220 - 220
  • [9] RESPONSE TO NILOTINIB IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) ACCORDING TO BCR-ABL MUTATIONS AT BASELINE
    Radich, J.
    Kim, D. -W
    Martinelli, G.
    Soverini, S.
    Branford, S.
    Mueller, M.
    Haque, A.
    Shou, Y.
    Hochhaus, A.
    Hughes, T.
    Saglio, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 55 - 55
  • [10] Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data
    Kantarjian, Hagop M.
    Jabbour, Elias
    Giles, Francis J.
    Bhalla, Kapil N.
    Pinilla-Ibarz, Javier
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Wang, Jim
    Woodman, Richard C.
    Baccarani, Michele
    le Coutre, Philipp D.
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 1278 - 1279
12345